PS1433 RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE

• Published in: HemaSphere 2019-06, Vol.3 (S1), p.660-661
• Main Authors: Tuğlular, A. Tülin, Elibol, T., Uzunoğlu, C., Aldağ, B., Dedeoğlu, Ö., Ercan, T., İpek, Y., Arıkan, F., Yılmaz, A.F., Atagündüz, I. Kaygusuz, Toptaş, T.
• Format: Article
• Language: English
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1097/01.HS9.0000564008.97747.a5

Background: Multiple Myeloma (MM) is a hematological malignancy in which renal involvement is common. Almost half of MM patients have increased creatinine levels at the time of diagnosis. In 20% of these patients, creatinine level is above 2 mg/dl. Kidney damage can be reversible in 50% of these patients. Aims: In this retrospective study, we evaluated the outcomes of autologous stem cell transplantation (ASCT) which was done in our center in multiple myeloma patients with renal failure. We compared the outcomes of these patients with patients with normal renal functions and who underwent ASCT. In patients with renal failure, melphalan 140 mg/m2 was used as conditioning regimen. Methods: We retrospectively analyzed the files of 574 patients with multiple myeloma in our center. We identified 106 patients who had ASCT between 2007–2018. We calculated creatinine clearances (CrCl) with Modification of Diet in Renal Disease (MDRD) formula at diagnosis. Patients were divided into 2 categories according to their CrCl results: patients with CrCl above 60 ml/min (n = 41), patients with CrCl below 60 ml/min (n = 28). Demographic data, laboratory results, pre‐transplant treatment and response to treatments were presented in Table 1. Results: Median follow‐up of the patients was 54 months. Median progression‐free survival (PFS) in patients with CrCl